Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Generation Bio ( (GBIO) ) is now available.
Generation Bio terminated its long-standing headquarters lease at 301 Binney Street in Cambridge effective Feb. 9, 2026, paying about $21.5 million in a termination fee while securing the return of a $2 million letter of credit. The company also ended its at-the-market stock offering program and shut down multiple equity incentive and employee stock purchase plans in conjunction with broader corporate changes.
On Feb. 9, 2026, XOMA Royalty Corp. completed its acquisition of Generation Bio via a tender offer followed by a merger, after 70% of outstanding shares were validly tendered at $4.2913 per share plus a contingent value right. Generation Bio’s shares are being delisted from Nasdaq, its SEC reporting obligations will be suspended, its board and senior management have been replaced by XOMA leadership, and the company now operates as a wholly owned subsidiary with amended charter and bylaws.
The most recent analyst rating on (GBIO) stock is a Sell with a $5.50 price target. To see the full list of analyst forecasts on Generation Bio stock, see the GBIO Stock Forecast page.
Spark’s Take on GBIO Stock
According to Spark, TipRanks’ AI Analyst, GBIO is a Underperform.
Generation Bio’s stock score is primarily impacted by its poor financial performance, characterized by declining revenues, high leverage, and negative cash flows. Technical analysis indicates bearish momentum, and the valuation is unattractive due to a negative P/E ratio and lack of dividend yield. These factors contribute to a low overall stock score.
To see Spark’s full report on GBIO stock, click here.
More about Generation Bio
Generation Bio Co. is a biotechnology company focused on research and development activities conducted from laboratory and office facilities in Cambridge, Mass. The company operated its headquarters at 301 Binney Street under a long-term lease, supporting its operations in the competitive life sciences hub around Kendall Square.
Average Trading Volume: 85,138
Technical Sentiment Signal: Sell
Current Market Cap: $35.98M
For detailed information about GBIO stock, go to TipRanks’ Stock Analysis page.